WHAT’S BEING CLAIMED:
- A new study shows that certain people are capable of passing super poops that can possibly treat IBD and type 2 diabetes.
- Poops from “super-donors” have the potential to double clinical remission rates of patients who receive their stool from fecal transplants.
- The head author and researcher from the University of Auckland believes that being able to pinpoint these “super-donors” can better the success rates of fecal transplants.
In a study published in Frontiers in Cellular and Infection Microbiology, poops from certain donors have been shown to have something exceptional about them. Something in their composition is capable of potentially treating inflammatory bowel disease (IBD) as well as type 2 diabetes.
Researchers from the University of Auckland conducted multiple trials and analyzed fecal transplants were able to pinpoint one particular donor whose poops had large amounts of the best and necessary bacteria.
Justin O’Sullivan, the senior author of the study and researcher at the University of Auckland, talks about how the microbiome can affect the treatment of complex disorders. He says that the existence of these “super-donors” was proved by the pattern of these trials.
Likely super-donors’ stool has the ability to “influence the host gut and to lead to clinical improvement.” Transplants from these donors have been seen to perhaps double the remaining average of clinical remission rates.
This isn’t the first study looking into the existence of “super poops”, however, this is the first to really give substance to their existence. Previous studies have shown that fecal transplants are a decent treatment for recurrent infections of the gut that can be serious.
However, fecal transplants seem to have less than 25% success rate when it comes to treating IBD and type 2 diabetes. Other studies suggest that results varied depending on the stool donor and the quality of the donation.
O’Sullivan explained, “It is well-known that responders typically exhibit a higher microbial diversity than non-responders.”
The general consensus is that a stable and diverse colony of bacteria in your gut is healthy. More successful stool samples showed that they did have more diverse, ‘keystone species’ of bacteria that were usually lacking in IBD patients.
O’Sullivan said, “Our hope is that if we can discover how this happens, then we can improve the success of fecal transplantation and even trial it for new microbiome-associated conditions like Alzheimer’s, multiple sclerosis and asthma.”
Source: Science Alert